Oppenheimer Adjusts Nektar Therapeutics Price Target to $3 From $5, Maintains Perform Rating
Oppenheimer Adjusts Nektar Therapeutics Price Target to $3 From $5, Maintains Perform Rating
奧本海默將納克塔爾治療藥物價格目標價格從 5 美元調整至 3 美元，維持表現評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊